The Union Budget 2026–27 has been met with optimism across India’s healthcare and biopharma ecosystem, with leaders praising the government’s strategic emphasis on chronic disease prevention, domestic manufacturing, digital health, and innovation. Finance Minister Nirmala Sitharaman’s announcement of the Biopharma Shakti Mission a dedicated programme to boost production of monoclonal antibodies, biosimilars, vaccines, and advanced therapies stood out as the most significant healthcare-related highlight, drawing widespread acclaim from industry stakeholders.

The mission includes enhanced production-linked incentives, capital subsidies, R&D grants, and faster regulatory pathways for indigenous biopharma products. Industry bodies such as the Indian Pharmaceutical Alliance (IPA), Organisation of Pharmaceutical Producers of India (OPPI), and Association of Indian Medical Device Industry (AiMeD) welcomed the move as a “much-needed push” to reduce import dependence (currently 60–70% for biologics) and strengthen India’s position in global supply chains.

Dilip Shanghvi, Chairman of Sun Pharmaceutical Industries, described the budget as “encouraging for innovation and manufacturing,” noting that the Biopharma Shakti Mission would create a stronger ecosystem for high-value biologics and support export growth. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, called it a “bold and timely step,” adding that full ownership consolidation of Biocon Biologics (enabled by the company’s recent QIP) would now align perfectly with the mission’s objectives.

Private hospital chains also reacted positively. Abhay Soi, Chairman & Managing Director of Max Healthcare, highlighted the increased allocation for NCD screening and primary care strengthening as a “welcome signal” for preventive health, while Dr. Prathap C. Reddy, Founder of Apollo Hospitals, praised the continued focus on digital health under ABDM and the potential for public-private partnerships in chronic care delivery.

The budget’s 18–22% rise in health sector spending, dedicated ₹8,000 crore envelope for chronic disease programmes, and support for telemedicine and home-based care received broad endorsement. Industry leaders noted that these measures would help reduce out-of-pocket expenditure, lower hospitalisation rates for preventable complications, and support value-based care models.

However, some voices called for faster implementation and greater clarity on execution. Dr. Girdhar Gyani, Director General of AHPI, urged the government to expedite rollout of NCD clinics in every district and ensure timely disbursal of incentives. Rajiv Nath, President of AiMeD, reiterated the need for calibrated tariff adjustments in the budget to further encourage local manufacturing.

Overall, the Union Budget 2026–27 has been interpreted as a strong vote of confidence in India’s healthcare and biopharma sectors. By prioritising prevention, manufacturing self-reliance, digital integration, and innovation, the government has set a clear direction that aligns with long-term public health and economic goals.